title: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders.
abstract: These practical guidelines for the biological treatment of personality disorders in primary care settings were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). They embody the results of a systematic review of all available clinical and scientific evidence pertaining to the biological treatment of three specific personality disorders, namely borderline, schizotypal and anxious/avoidant personality disorder in addition to some general recommendations for the whole field. The guidelines cover disease definition, classification, epidemiology, course and current knowledge on biological underpinnings, and provide a detailed overview on the state of the art of clinical management. They deal primarily with biological treatment (including antidepressants, neuroleptics, mood stabilizers and some further pharmacological agents) and discuss the relative significance of medication within the spectrum of treatment strategies that have been tested for patients with personality disorders, up to now. The recommendations should help the clinician to evaluate the efficacy spectrum of psychotropic drugs and therefore to select the drug best suited to the specific psychopathology of an individual patient diagnosed for a personality disorder.
authors.affiliation: Department of Psychiatry and Psychotherapy, Rostock University, Rostock, Germany. sabine-herpertz@med.uni-rostock.de
authors.forename: Sabine C
authors.initials: SC
authors.lastname: Herpertz
authors.forename: Mary
authors.initials: M
authors.lastname: Zanarini
authors.forename: Charles S
authors.initials: CS
authors.lastname: Schulz
authors.forename: Larry
authors.initials: L
authors.lastname: Siever
authors.forename: Klaus
authors.initials: K
authors.lastname: Lieb
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D000928:Antidepressive Agents / Q000145:classification / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001883:Borderline Personality Disorder / Q000145:classification / Q000188:drug therapy / Q000628:therapy; D019317:Evidence-Based Medicine; D006801:Humans; D010554:Personality Disorders / Q000145:classification / Q000188:drug therapy / Q000628:therapy*; D011570:Psychiatry / Q000592:standards*; D011613:Psychotherapy / Q000379:methods; D012569:Schizotypal Personality Disorder / Q000188:drug therapy / Q000628:therapy; D012955:Societies, Medical / Q000592:standards*
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents